The US Food and Drug Administration (FDA)-approved treatments for metastatic melanoma, including immune checkpoint blocking antibodies (such as anti-CTLA-4 and anti-PD-1), have an effect on reducing population mortality (18). This evidence concerns the gene CTLA4 and metastatic melanoma.